Indice di infiammazione
intestinale
Calprotectina, il test per individuare pazienti con possibile infiammazione dell'intestino: scopri i test disponibili e il loro funzionamento
 
Bibliografia
Aadland E, Fagerhol MK. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Europ J Gastroenterol Hepatol 2002; 14: 1.
pmid: 12172400 http://www.ncbi.nlm.nih.gov/pubmed/12172400

Andersson KB, Sletten K, Berntzen HB, Dale I, Brandtzaeg P, Jellum E, Fagerhol MK. The leucocyte L1 protein: identity with the cystic fibrosis antigen and the calcium-binding MRP-8 and MRP-14 macrophage components. Scand J Immunol 1988; 28(2): 241-5.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/3413449

Baldassarre ME, Fanelli M, Lasorella ML, Laneve A, Grosso R, Falcone MR, Laforgia N.Fecal calprotectin (FC) in newborns: is it a predictive marker of gastrointestinal and/or allergic disease? Immunopharmacol Immunotoxicol. 2011 Mar;33(1):220-3. Epub 2010 Jul 5.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/20602542

Baldassarre ME, Altomare MA, Fanelli M, Carbone D, Di Bitonto G, Mautone A, Laforgia N Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease? Endocr Metab Immune Disord Drug Targets. 2007 Mar;7(1):1-5. Review.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/17346198

Berni Canani R, Rapacciuolo L, Romano MT, Tanturri de Horatio L, Terrin G, Manguso F, Cirillo P, Paparo F, Troncone R. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis. 2004 Jul;36(7):467-70.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/15285526

Berntzen HB, Fagerhol MK. L1, a major granulocyte protein: antigenic properties of its subunits. Scand J Clin Lab Invest 1988; 48(7): 647-52.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/3144035

Berntzen HB, Olmez U, Fagerhol MK, Munthe E. The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1991; 20(2): 74-82.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/1709519

Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993; 34(10): 1357-63.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/8244101

Bjarnason I, Sherwood R. Fecal calprotectin: a significant step in the noninvasive assessment of intestinal inflammation. J Pediatr Gastroent Nutr 2001; 33: 11.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/11479401

Brandtzaeg P, Gabrielsen TO, Dale I, Muller F, Steinbakk M, Fagerhol MK. The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor in epithelial surfaces. Adv Exp Med Biol 1995; 371A: 201-6.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/8525906

Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 32(2): 171-7
pmid: http://www.ncbi.nlm.nih.gov/pubmed/11321388

Campeotto F, Baldassarre M, Butel MJ, Viallon V, Nganzali F, Soulaines P, Kalach N, Lapillonne A, Laforgia N, Moriette G, Dupont C, Kapel N Fecal calprotectin: cutoff values for identifying intestinal distress in preterm infants. J Pediatr Gastroenterol Nutr. 2009 Apr;48(4):507-10.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/19322064

Campeotto F, Baldassarre M, Butel MJ, Viallon V, Nganzali F, Soulaines P, Kalach N, Lapillonne A, Laforgia N, Moriette G, Dupont C, Kapel N. Fecal calprotectin: cutoff values for identifying intestinal distress in preterm infants.J Pediatr Gastroenterol Nutr. 2009 Apr;48(4):507-10.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/19322064

Campeotto F, Kalach N, Lapillonne A, Butel MJ, Dupont C, Kapel N. Time course of faecal calprotectin in preterm newborns during the first month of life. Acta Paediatr. 2007 Oct;96(10):1531-3. Epub 2007 Aug 20. No abstract available.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/17714537

Campeotto F, Butel MJ, Kalach N, Derrieux S, Aubert-Jacquin C, Barbot L, Francoual C, Dupont C, Kapel N. High faecal calprotectin concentrations in newborn infants. Arch Dis Child Fetal Neonatal Ed. 2004 Jul;89(4):F353-5.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/15210674

Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008 Jul;40(7):547-53. Epub 2008 Mar 20.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/18358796

Canani RB, de Horatio LT, Terrin G, Romano MT, Miele E, Staiano A, Rapacciuolo L, Polito G, Bisesti V, Manguso F, Vallone G, Sodano A, Troncone R. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006 Jan;42(1):9-15.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/16385247

Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, Scalici C, Montalto G, Di Fede G, Rini G, Notarbartolo A, Averna MR. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003 Jun;49(6 Pt 1):861-7.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/12765980

Carroccio A, Rocco P, Rabitti PG, Di Prima L, Forte GB, Cefalù AB, Pisello F, Geraci G, Uomo G. Plasma calprotectin levels in patients suffering from acute pancreatitis. Dig Dis Sci. 2006 Oct;51(10):1749-53.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/16964544

Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease Gut. 2005 Mar;54(3):364-8.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/15710984

Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, Sterpi C, Marchi S, Maltinti G.. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003 Sep;35(9):642-7.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/14563186

D'Incà R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, Oliva L, Sturniolo GC Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008 Aug;103(8):2007-14.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/18802997

D'Incà R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007 Apr;22(4):429-37. Epub 2006 Jul 13.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/16838143

Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. Europ J Biochem 1983; 134(1): 1-6.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/6861753

Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 2000; 356(9244):1783-4.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/11117904

Fagerhol MK, Andersson KB, Naess-Andresen CF, Brandtzaeg P, Dale I. Calprotectin (The L1 Leukocyte Protein) In: VL Smith & JR Dedman (Eds): Stimulus Response Coupling. The Role of Intracellular Calcium-Binding Proteins, CRC Press, Boca Raton, Fla., USA, 1990, pp. 187-210.
Gilbert JA, Ahlquist DA, Mahoney DW, Zinsmeister AR, Rubin J, Ellefson RD. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin. Scand J Gastroenterol 1996; 31(10):1001-5.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/8898421

Johne B, Kronborg O, Ton HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001; 36(3): 291-6.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/11305517

Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, Dale I. Functional and clinical aspects of the myelomonocyte protein calprotectin. Molecular Pathology 1997; 50(3):113-23.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/9292145

Josefsson S, Bunn SK, Domellöf M. Fecal calprotectin in very low birth weight infants. J Pediatr Gastroenterol Nutr. 2007 Apr;44(4):407-13.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/17414135

Kristinsson J, Armbruster CH, Ugstad M, Kriwanek S, Nygaard K, Ton H, Fuglerud P. Fecal excretion of calprotectin in colorectal cancer; relationship to tumor characteristics. Scand J Gastroenterol 2001; 36(2):202-7.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/11252414

Kristinsson J, Roseth A, Fagerhol MK, Aadland E, Schjonsby H, Bormer OP, Raknerud N, Nygaard K. Fecal calprotectin concentration in patients with colorectal carcinoma. Disease of the Colon & Rectum1998; 41(3):316-21.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/9514426

Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH, Vellacott K, Moshakis V, Reynolds JR. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000; 46(6):795-800.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/10807890

Kapel N, Campeotto F, Kalach N, Baldassare M, Butel MJ, Dupont C. Faecal calprotectin in term and preterm neonates. J Pediatr Gastroenterol Nutr. 2010 Nov;51(5):542-7. Review.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/20818270

Kapel N, Roman C, Caldari D, Sieprath F, Canioni D, Khalfoun Y, Goulet O, Ruemmele FM. Fecal tumor necrosis factor-alpha and calprotectin as differential diagnostic markers for severe diarrhea of small infants.J Pediatr Gastroenterol Nutr. 2005 Oct;41(4):396-400.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/16205505

Kapel N, Barbot L, Gobert JG. New fecal markers: recent developments and perspectives. Ann Pharm Fr. 2004 Nov;62(6):371-5. Review. French.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/15550893

Kapel N. Faecal inflammatory markers in nutrition and digestive Disease in children. Arch Pediatr. 2004 May;11(5):403-5. Review. French. No abstract available.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/15135420

Laforgia N, Baldassarre ME, Pontrelli G, Indrio F, Altomare MA, Di Bitonto G, Mautone A. Calprotectin levels in meconium. Acta Paediatr. 2003 Apr;92(4):463-6.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/12801114

Limburg PJ. Ahlquist DA. Sandborn WJ. Mahoney DW. Devens ME. Harrington JJ. Zinsmeister AR. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. American Journal of Gastroenterology 2000; 95(10):2831-7.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/11051356

Meucci G, D'Incà R, Maieron R, Orzes N, Vecchi M, Visentini D, Minoli G, Dal Pont E, Zilli M, Benedetti E, Virgilio T, Tonutti E. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study. Dig Liver Dis. 2010 Mar;42(3):191-5. Epub 2009 Aug 19.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/19695969

Montalto M, Gallo A, Ferrulli A, Visca D, Campobasso E, Cardone S, D'Onofrio F, Santoro L, Covino M, Mirijello A, Leggio L, Gasbarrini G, Addolorato G. Fecal calprotectin concentrations in alcoholic patients: a longitudinal study. Eur J Gastroenterol Hepatol. 2011 Jan;23(1):76-80.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/21030869

Montalto M, Gallo A, Ianiro G, Santoro L, D'Onofrio F, Ricci R, Cammarota G, Covino M, Vastola M, Gasbarrini A, Gasbarrini G. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J Gastroenterol. 2010 Jul 21;16(27):3406-10.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/20632443

Montalto M, Gallo A, Curigliano V, D'Onofrio F, Santoro L, Covino M, Dalvai S, Gasbarrini A, Gasbarrini G Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy - a randomized, double-blind, cross-over, placebo-controlled study. Aliment Pharmacol Ther. 2010 Jul;32(2):209-14. Epub 2010 Apr 7.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/20384610

Montalto M, Santoro L, Dalvai S, Curigliano V, D'Onofrio F, Scarpellini E, Cammarota G, Panunzi S, Gallo A, Gasbarrini A, Gasbarrini G. Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. Dig Dis. 2008;26(2):183-6. Epub 2008 Apr 21.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/18431069

Montalto M, Santoro L, Curigliano V, D'Onofrio F, Cammarota G, Panunzi S, Ricci R, Gallo A, Grieco A, Gasbarrini A, Gasbarrini G. Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol. 2007 Aug;42(8):957-61.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/17613925

Montalto M, Curigliano V, Santoro L, Armuzzi A, Cammarota G, Covino M, Mentella MC, Ancarani F, Manna R, Gasbarrini A, Gasbarrini G. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am J Gastroenterol. 2007 Jan;102(1):132-6. Epub 2006 Nov 13.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/17100982

Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 2002; 91: 45.
Roseth AG. Fagerhol MK. Aadland E. Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scandinavian Journal of Gastroenterology 1992; 27(9):793-8.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/10686275

Roseth AG. Aadland E. Jahnsen J. Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion1997; 58(2):176-80.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/9144308

Roseth AG. Schmidt PN. Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1999; 34(1):50-4.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/10048733

Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27(9):793-8.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/1411288

Roseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K, Roald B. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993; 28(12):1073-6.
pmid:
http://www.ncbi.nlm.nih.gov/pubmed/8303210

Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004 Oct;39(10):1017-20.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/15513345

Scarpa M, D'Incà R, Basso D, Ruffolo C, Polese L, Bertin E, Luise A, Frego M, Plebani M, Sturniolo GC, D'Amico DF, Angriman I. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Dis Colon Rectum. 2007 Jun;50(6):861-9.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/17473939

Tibble JA, Bjarnason I. Department of Medicine, Guy's, King's, St Thomas's Medical School, Bessemer Road, London SE5 9PJ, UK.Non-invasive investigation of flammatory bowel disease.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/11819811

Tibble JA, Bjarnason I. Department of Medicine, Guy's, King's, St. Thomas's Medical School, London, UK. Fecalcalprotectin as an index of intestinal inflammation.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/12783101

Tibble JA. Sigthorsson G. Bridger S. Fagerhol MK. Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. [Journal Article] Gastroenterology 2000; 119(1):15-22.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/10889150

Tibble JA. Sigthorsson G. Foster R. Scott D. Fagerhol MK. Roseth A. Bjarnason I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999; 45(3):362-6.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/10446103

Tibble J. Teahon K. Thjodleifsson B. Roseth A. Sigthorsson G. Bridger S. Foster R. Sherwood R. Fagerhol M. Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47(4):506-13.

Tibble J, Sigthorsson G, Foster R, Fagerhol MK, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001; 49: 402.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/11511563

Tibble JA, Bjarnason I. Markers of intestinal inflammation and predictors of clinical relapse in patients with quiescent IBD. Medscape Gastroenterol 2001; 3 (2).

Ton H. Brandsnes. Dale S. Holtlund J. Skuibina E. Schjonsby H. Johne B. Improved assay for fecal calprotectin. Clinica Chimica Acta 2000; 292(1-2):41-54.
pmid: http://www.ncbi.nlm.nih.gov/pubmed/10686275

 

 
Eurospital Spa - Via Flavia 122 - 34147 Trieste - P.IVA: 00047510326
C.S. € 2582000 - CF e Reg. Impr. 00047510326 - REA TS 38955